Koenraad Blot
Nessuna posizione attualmente
Profilo
Koenraad Blot worked as an Executive Director of Clinical Research at Theratechnologies, Inc., Head of Medical Affairs and Clinical Operations at Pfizer Inc., and Chief Medical Officer at TiGenix NV and elbion NV.
He holds a doctorate from Ghent University and an undergraduate degree from the University of Antwerp.
Precedenti posizioni note di Koenraad Blot
| Società | Posizione | Fine |
|---|---|---|
| TIGENIX NV | Direttore Tecnico/Scientifico/R&S | - |
| THERATECHNOLOGIES INC. | Direttore Tecnico/Scientifico/R&S | - |
| PFIZER, INC. | Direttore Tecnico/Scientifico/R&S | - |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Koenraad Blot
| Ghent University | Doctorate Degree |
| University of Antwerp | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
- Borsa valori
- Insiders
- Koenraad Blot
